(Q48188853)

English

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

author name string

William A Ball

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Duane B Snavely

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Richard J Hargreaves

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Armin Szegedi

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Christopher Lines

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Scott A Reines

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

publication date

20 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

29

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

568-577

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Aprepitant: a review of its use in the prevention of nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Major depressive disorder treatment guidelines in America and Europe

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

The role of substance P in stress and anxiety responses

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

New insights into the antidepressant actions of substance P (NK1 receptor) antagonists

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

21 January 2018

A study comparing paroxetine placebo and imipramine in depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine: safety and tolerability issues

1 reference

https://api.crossref.org/works/10.1002%2FHUP.2444

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.2444

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25330122

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48188853&oldid=2188970034"